Metraipolis › archive › dc_189d22b9167a

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42114019
DOI
10.2196/81323
License (as archived)
solo-consultazione
Archived
2026-11-02T12:28:44.997Z
SHA-256 of the archived text
65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b
Stable URL of this page
https://metraipolis.com/documento/dc_189d22b9167a

How to cite

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019 — Europe PMC (en), https://europepmc.org/article/MED/42114019 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_189d22b9167a (Metraipolis archive dc_189d22b9167a, sha256 65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b)
BibTeX
@misc{dc189d22b9167a,
  title = {Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42114019},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_189d22b9167a; sha256 65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42114019. Agents can read the archived copy with the MCP tool read_document.